• Home
• About us
• Contact

• News
• People
• Products
• Deals
• Organisations

• » Follow us on twitter!
• » Get Free Newsletter!

Advertisement

Organisation › Details

Ascendis Pharma A/S (Nasdaq: ASND)

Ascendis Pharma is an emerging pharmaceutical company which is creating improved, patentable versions of both currently marketed drugs and high-value development-stage opportunities. The company is built upon a novel transient linker technology, which conjugates peptides, proteins and small molecules to a carrier molecule in a reversible fashion. This unique reversibility allows an unmodified active drug to be released (unlinked) in the body in a precise, time-controlled fashion, creating a long-acting effect. Conventional conjugation technologies are unable to achieve this type of slow-release mechanism because the polymer cannot de-link from the drug.

Ascendis’ commercial headquarters is based in Copenhagen, Denmark. Its research organization, formerly known as Complex Biosystems, is located in Heidelberg, Germany. The expertise at the two sites creates a continuum from discovery to clinical development and commercialization that facilitates rapid product development. *

 

	Start	2007-12-01 established
	Group	Ascendis Pharma (Group)
	Today	Ascendis Pharma (Group)
	Industry	TransCon technology
	Industry 2	pharmaceutical
	Person	Mikkelsen, Jan (Ascendis Pharma 201609 CEO)
	Person 2	Smith, Scott T. (Ascendis Pharma 201609 CFO)
	Region	Hellerup
	Country	Denmark
	Street	12 Tuborg Boulevard
	City	2900 Hellerup
	Tel	+45-3694-4486
		Address record changed: 2020-12-02
Basic data	Employees	D: 101 to 500 (2017-12-31)
	Currency	EUR
	Annual sales	1,530,000 (revenue, consolidated (2017) 2017-12-31)
	Profit	-123,897,000 (2017-12-31)
	Cash	690,400,000 (2019-06-30)
		* Document for �About Section�:
		Record changed: 2020-05-19

Advertisement

More documents for Ascendis Pharma (Group)

• [1] Ascendis Pharma A/S. (5/11/20). "Press Release: Ascendis Pharma A/S Will Appoint Jesper Høiland as Global Chief Commercial Officer". Copenhagen....
• [2] Ascendis Pharma A/S. (8/29/19). "Press Release: Ascendis Pharma A/S Announces Three Investor Presentations in September". Copenhagen....
• [3] Ascendis Pharma A/S. (3/4/18). "Press Release: Ascendis Pharma Announces Once-weekly TransCon Growth Hormone Demonstrated Superiority on Primary Endpoint Compared to a Daily Growth Hormone in Phase 3 heiGHt Trial for Pediatric Growth Hormone Deficiency"....
• [4] Ascendis Pharma A/S. (3/4/18). "Press Release: Ascendis Pharma A/S Announces Proposed Public Offering of ADSs". Copenhagen....
• [5] Ascendis Pharma A/S. (4/2/18). "Press Release: Ascendis Pharma A/S Appoints Thomas A. Larson as Chief Commercial Officer". Copenhagen....
• [6] Ascendis Pharma A/S. (3/28/18). "Press Release: Ascendis Pharma A/S Reports Full Year 2017 Financial Results". Copenhagen....
• [7] Ascendis Pharma A/S. (3/19/18). "Press Release: Ascendis Pharma Announces Two Posters on Rare Disease Pipeline Programs at ENDO 2018". Copenhagen....
• [8] Ascendis Pharma A/S. (2/21/18). "Press Release: Ascendis Pharma A/S Announces Pricing of Public Offering of ADSs". Copenhagen....
• [9] Ascendis Pharma A/S. (2/20/18). "Press Release: Ascendis Pharma A/S Announces Proposed Public Offering of ADSs". Copenhagen....
• [10] Ascendis Pharma A/S. (12/21/17). "Press Release: Ascendis Pharma A/S Announces Participation in 36th Annual J.P. Morgan Healthcare Conference". Copenhagen....

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)

Advertisement

» top

» Imprint  |  » Data Privacy  |  » Contact  |  The use of this website requires to accept the » Disclaimer!   |  A project of [iito] Business Intelligence © 2002-2021. Made in Germany.